Great Bay Bio successfully hosted the Future Technology: AI Empowering Bioprocessing Development summit at the Suzhou International Expo Center, marking a celebration of technological innovation. The event saw the official introduction of AlfaOPA™, an AI-enabled culture media development platform developed by Great Bay Bio. This platform revolutionizes traditional culture media development by integrating AI to optimize culture media, eliminating the need for blind screening.

The launch of AlfaOPA™ is a significant step forward for Great Bay Bio's CMC platform, advancing its AI-driven cell engineering capabilities. This platform signifies the completion of a comprehensive business system centered around "cell engineering," incorporating "cell line construction" and "culture media development."

AlfaOPA™ combines Great Bay Bio's dry and wet experimental platforms to create metabolic models for multiple cell lines. Through comparisons and simulations, optimized supplements are generated, streamlining culture media development. This platform is adaptable to various cell lines without requiring the replacement of existing media. Initial customer data reveals an average over 30% increase in protein expression level for formulas optimized with AlfaOPA™, while maintaining consistent protein quality.

Kingsley Leung, GBB's chairman and co-founder, expressed his enthusiasm for discussing the industry's future in Suzhou. AlfaOPA™ aligns with Great Bay Bio's goal of enhancing drug development productivity through technological innovation and market-driven demand. This AI-driven culture media development platform, combined with their site-specific integration cell line platform, maximizes product potential. The launch of AlfaOPA™ ushers in a new era in AI-powered culture media development technology, emphasizing its market-oriented approach.

More Information : https://www.techdogs.com/tech-news/pr-newswire/ai-media-development-platform-alfaopa-officially-launched